Boehringer Japan Aims to Maintain Top Combined COPD Market Share for LAMA/LABA Combos, LAMA Monodrugs

Mr Hara (right) and Mr Suga Nippon Boehringer Ingelheim aims to maintain its top shares in the Japanese COPD markets for long-acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) combination therapies and LAMA monodrugs, by way of approaching more diverse medical...read more